Diabetes Nutrition Market is estimated to be valued at USD 6,921.3 Mn in 2026 and is expected to reach USD 10,897.8 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033. Diabetes nutrition include proteins, amino acids, omega-3 fatty acids, alpha-lipoic acid, herbal supplements, soluble fiber, probiotics, carbohydrates, and antioxidants. Diabetes nutrition helps the body to lower the blood glucose level, as extra calories and fats creates the undesirable rise in blood glucose level.
Figure 1. Global Diabetes Nutrition Market Share (%), by Form, 2026

To learn more about this report, Download Free Sample
Global Diabetes Nutrition Market - Driver
Increasing strategies adopted by key market players, such as product launches, is expected to drive the global diabetes nutrition market over the forecast period. For instance, in June 2020, Pendulum, a biotechnology company, announced that they had launched pendulum glucose control, the first medical probiotic for the dietary management of type 2 diabetes. Pendulum glucose control targets the gut microbiome to manage blood sugar level.
Diabetes Nutrition Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6,921.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.7% | 2033 Value Projection: | USD 10,897.8 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Abbott., Reckitt Benckiser Group PLC., Hexagonnutrition Ltd., Nestlé, Danone, Baxter, Fresenius Kabi AG, B. Braun SE, Furious Nutritions, Nature's One, Otsuka Pharmaceutical Factory, Inc., Scientific Brain Nutraceutical Pvt. Ltd., Centrum (GSK plc.), BASF SE, DSM, Zeon Lifesciences Ltd., Zenova Bio Nutrition, Nuflower Foods & Nutrition Pvt. Ltd., KD Chem Pharma, Pentasure Nutrition, Akums Drugs and Pharmaceuticals Ltd., Bionova, Zoic Pharmaceuticals., Fermentis Life Sciences, Other Prominent Players, |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Figure 2. Global Diabetes Nutrition Market Share (US$ Million), by Region, 2026

To learn more about this report, Download Free Sample
Global Diabetes Nutrition Market: Key Developments
The adoption of inorganic growth strategies such as product launches by key market players is expected to drive the global diabetes nutrition market growth. For instance, in December 2021, Danone India, a manufacturer of nutrion products, announced that they had launched Protinex Diabetes Care to address the nutritional requirements of Indians with diabetes. The product aims to provide adequate protein and fiber, which are important nutrients in managing blood sugar levels.
Global Diabetes Nutrition Market: Restraint
Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration is expected to hinder the market growth. For instance, in November 2020, the U.S. Food and Drug Administration recalled metformin hydrochrolide,a medication for glucose management in patients with type 2 diabetes which was manufactured by Marksans Pharma, a pharmaceutical company. The drug was recalled due the detection of of high levels of N-nitrosodimethylamine, an organic compound linked to causing cancer in high concentrations.
Global Diabetes Nutrition Market - Key Players
Major players operating in the global diabetes nutrition market include Abbott., Reckitt Benckiser Group PLC., Hexagonnutrition Ltd., Nestlé, Danone, Baxter, Fresenius Kabi AG, B. Braun SE, Furious Nutritions, Nature's One, Otsuka Pharmaceutical Factory, Inc., Scientific Brain Nutraceutical Pvt. Ltd., Centrum (GSK plc.), BASF SE, DSM, Zeon Lifesciences Ltd., Zenova Bio Nutrition, Nuflower Foods & Nutrition Pvt. Ltd., KD Chem Pharma, Pentasure Nutrition, Akums Drugs and Pharmaceuticals Ltd., Bionova, Zoic Pharmaceuticals., Fermentis Life Sciences, Other Prominent Players,
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients